HER2 TOP2A Meta-Anal Study Group (Including:

). (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data. Lancet Oncology, Vol.12 (No.12). pp. 1134-1142. ISSN 1470-2045

Full text not available from this repository.

Abstract

Background: Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer. Methods: We did a meta-analysis of individual patient data from five randomised adjuvant trials that compared anthracycline-based regimens with cyclophosphamide, methotrexate, and fluorouracil (CMF) regimens. We assessed the status of HER2 and TOP2A genes with fluorescent in-situ hybridisation. Tumour samples were submitted to an external laboratory for validation. We calculated hazard ratios (HR) to compare event-free survival (EFS) and overall survival in patients receiving anthracycline-based treatment with those receiving CMF in two HER2 cohorts (HER2 amplified and non-amplified tumours) and in three TOP2A cohorts (normal, amplified, and deleted tumours). Findings: We analysed data for 3452 patients for HER2 and 3102 patients for TOP2A. For EFS, HRs were 0.89 (95% CI 0.79-1.01) for HER2 non-amplified patients and 0.71 (0.58-0.86) for HER2-amplified patients (p(interaction) = 0.0485); for overall survival, HRs were 0.91 (95% CI 0.79-1.05) for HER2 non-amplified patients and 0.73 (0.59-0.89) for HER2-amplified patients (p(interaction) = 0.0718). In analysis of TOP2A status, HRs for EFS were 0.88 (0.78-1.00) for normal, 0.63 (0.46-0.87) for deleted, and 0.62 (0.43-0.90) for amplified (p(interaction) = 0.0513); HRs for overall survival were 0.89 (0.78-1.03) for normal, 0.68 (0.49-0.95) for deleted, and 0.67 (0.46-0.98) for amplified (p(interaction) = 0.1608). When patients with TOP2A-deleted and TOP2A-amplified tumours were grouped together (altered cohort) and compared with data from patients with normal TOP2A tumours, HRs for EFS were 0.64 (0.50-0.81) for altered and 0.88 (0.78-1.00) for normal (p(interaction) = 0.0183); HRs for overall survival were 0.67 (0.52-0.86) for altered and 0.89 (0.78-1.03) for normal (p(interaction) = 0.0455). Interpretation: Although HER2 amplification and combined TOP2A amplification and deletion may have some value in the prediction of responsiveness to anthracycline-based chemotherapy, our findings do not support the use of anthracyclines only in patients with HER2-amplified or TOP2A-aberrated tumours.

Item Type:	Journal Article
Subjects:	Q Science > QP Physiology R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	DNA topoisomerase II, Anthracyclines, Methotrexate, Chemotherapy, Gene amplification, Fluorouracil, Breast -- Cancer -- Treatment
Journal or Publication Title:	Lancet Oncology
Publisher:	Elsevier Science BV
ISSN:	1470-2045
Date:	November 2011
Volume:	Vol.12
Number:	No.12
Page Range:	pp. 1134-1142
Identification Number:	10.1016/S1470-2045(11)70231-5
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	Pfizer Inc., Associazione Italiana Ricerca Cancro [Italian Association for Cancer Research] (AIRC), Abbott Laboratories, Suomen Akatemia [Academy of Finland], Belgian Federation Against Cancer, Cancer Research UK, Amis de l'Institut Bordet, Scottish Breast Cancer Trials Group, Queen's University (Kingston, Ont.). NCIC Clinical Trials Group, Canadian Cancer Society Research Institite (CCSRI), Danish Council for Strategic Research, Pharmacia & Upjohn
References:	1 Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260–66. 2 Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361–70. 3 Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15. J Natl Cancer Inst 2000; 92: 1991–98. 4 Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103–11. 5 Järvinen TA, Tanner M, Rantanen V, et al. Amplifi cation and deletion of topoisomerase II alpha associate with ErbB-2 amplifi cation and aff ect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156: 839–47. 6 Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplifi cation and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fl uorouracil. Clin Cancer Res 2002; 8: 1107–16. 7 Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. Cancer Res 2009; 69: 24s (abstr 62). 8 Press MF, Sauter G, Buyse M E, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011; 29: 859–67. 9 Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ. Type 1 receptor tyrosine kinase profi les identify patients with enhanced benefi t from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 2008; 26: 5027–35. 10 Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifi cations and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fl uorouracil or cyclophosphamide, epirubicin, and fl uorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483–90. 11 O’Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009; 101: 644–50. 12 Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Breast Cancer Res Treat 2008, 107: 24s (abstr 705). 13 Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fl uorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fl uorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651–58. 14 Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fl uorouracil in node-positive breast cancer. J Clin Oncol 200; 19: 3103–10. 15 Ejlertsen B, Mouridsen HT, Jensen MB, et al. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007; 43: 877–84. 16 Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fl uorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006; 355: 1851–62. 17 Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790–800. 18 Gennari A, Sormani MP, Pronzato P, et al. HER2 status and effi cacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100: 14–20. 19 Dhesy-Thind B, Pritchard KI, Messersmith H, O’Malley F, Elavathil L, Trudeau M. Her-2/neu in systemic therapy for women with breast cancer: a systemic review. Breast Cancer Res Treat 2008; 109: 209–29. 20 Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol 2010; 28: 2784–95. 21 Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–52. 22 Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classifi cation and prognosis based on gene expression profi les from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393–98. 23 Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736–50. 24 Durbecq V, Desmedt C, Paesmans M, et al. Correlation between topoisomerase-II alpha gene amplifi cation and protein expression in HER-2 amplifi ed breast cancer. Int J Oncol 2004; 25: 1473–79. 25 Campiglio M, Somenzi G, Olgiati C, et al. Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer 2003; 105: 568–73. 26 Mueller RE, Parkes RK, Andrulis I, O’Malley FP. Amplifi cation of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004; 39: 288–97. 27 Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40: 205–11. 28 Di Leo A, Moretti E. Anthracyclines: the fi rst generation of cytotoxic targeted agents? A possible dream. J Clin Oncol 2008; 26: 5011–13. 29 Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefi t: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 2010; 11: 266–74. 30 Ejlertsen B, Jensen MB, Nielsen KV, et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 2010; 28: 984–90. 31 Farmer P, Bonnefoi H, Anderle P, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15: 68–74. 32 Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011; 29: 1578–86.
URI:	http://wrap.warwick.ac.uk/id/eprint/40322

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item